FDA panel backs Achaogen's plazomicin for cUTI, not bloodstream infections

An FDA panel split on the indications being considered for plazomicin (formerly ACHN-490). FDA’s Antimicrobial Drugs Advisory Committee voted 15-0 in favor of approving plazomicin to treat complicated urinary tract infections (cUTIs) and 11-4

Read the full 343 word article

User Sign In